MDS: higher risk patients may still benefit from ICT

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Iron chelating therapy (ICT) with oral deferasirox (DFX) in patients with higher risk myelodysplastic syndromes (MDS) delivered outcomes comparable to those seen with ICT on low-risk disease.

Why this matters

  • Iron overload is common in transfusion-dependent patients, but ICT i...